C4 Therapeutics Inc. (CCCC) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, C4 Therapeutics Inc. (NASDAQ: CCCC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.21 (-4.75% 1D, market cap $414.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CCCC ranks #827 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CCCC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $410.1M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $407.7M). Among the 5-stock peer group, CCCC leads on earnings multiple (N/A) while CCCC leads on capital efficiency (-35.0% ROIC).
Per CCCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662579), C4 Therapeutics Inc. generated $35.9M in revenue (+1.0% YoY), -$105.0M in net income, and -$99.3M in free cash flow against $359.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 44% of 52W Range • RSI-14 at 56.6 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CCCC currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.29) and Max Pain ($3.37) forces dealer call-delta covering toward $5.43.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
C4 Therapeutics Inc. (CCCC) dropped -4.75% to $3.21, trading at 44% of its 52-week range ($1.69 – $5.17). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead StageWATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopha
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CCCC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CCCC. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, C4 Therapeutics Inc. (CCCC) ranks #827 by composite RQD confidence (29/100, grade E) and #467 by equity capitalization ($414.6M). Within this direct 5-issuer industry benchmark cohort, CCCC leads on earnings valuation at N/A trailing P/E, while CCCC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CCCC at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CCCC
ACTIVE
C4 Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -4.75% | $414.6M | Benchmark Subject |
| EDIT Editas Medicine Inc. | E | 29/100 | — | — | -35.0% | -3.74% | $410.1M | /edit-vs-cccc → |
| ALLO Allogene Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -7.63% | $407.7M | /allo-vs-cccc → |
| AUTL Autolus Therapeutics plc | E | 21/100 | — | -27.8% | -35.0% | -6.58% | $404.6M | /autl-vs-cccc → |
| PROK ProKidney Corp. (Class A) | D- | 35/100 | — | — | -35.0% | -13.51% | $391.6M | /prok-vs-cccc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), C4 Therapeutics Inc. (CCCC) reported GAAP revenue of $35.9M (+1.0% vs. FY2024 revenue of $35.6M , and +73.2% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$98.7M, and free cash flow of -$99.3M (-52.0% YoY). On the balance sheet, CCCC closed FY2025 with $359.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.9M | -$105.0M | -$98.7M | -$99.3M | $359.1M | — |
| FY2024 (FY) | 2024-12-31 | $35.6M | -$105.3M | -$65.2M | -$65.3M | $349.6M | — |
| FY2023 (FY) | 2023-12-31 | $20.8M | -$132.5M | -$106.8M | -$106.8M | — | — |
As of 2026-11-03, C4 Therapeutics Inc. (NASDAQ: CCCC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.21 (-4.75% 1D, market cap $414.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CCCC ranks #827 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CCCC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $410.1M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $407.7M). Among the 5-stock peer group, CCCC leads on earnings multiple (N/A) while CCCC leads on capital efficiency (-35.0% ROIC).
Per CCCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662579), C4 Therapeutics Inc. generated $35.9M in revenue (+1.0% YoY), -$105.0M in net income, and -$99.3M in free cash flow against $359.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CCCC last traded at $3.21 (-4.75% on volume of 2,861,882 shares), positioning the stock -2.43% below its 50-day simple moving average ($3.29) and -0.31% below its 200-day simple moving average ($3.22). Across its 52-week range of $1.69 to $5.17, CCCC sits at the 43.7% percentile with a 14-day RSI of 56.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.81 to $3.61).
C4 Therapeutics Inc. (CCCC) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.21 (-4.75% 1D, market capitalization $414.6M).
C4 Therapeutics Inc. (CCCC) is listed on NASDAQ and operates in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.4B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), C4 Therapeutics Inc. (CCCC) reported $35.9M in annual revenue (up from $35.6M in FY2024, +1.0% YoY) and -$105.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($20.8M revenue, -$132.5M net income) through FY2025, CCCC scaled operating cash flow to -$98.7M and free cash flow to -$99.3M, backed by $359.1M in total assets against $0 in total debt.
The sector and industry classification is the only sector context provided.
Real-time company headlines, analyst actions, and sector developments for C4 Therapeutics Inc. (CCCC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on CCCC here at $3.37: Institutional accumulation and options positioning score 10/20 and a JPMorgan Overweight initiation is in the news feed.. Compare CCCC's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $3.20 are getting bought.
Both sides have a point here — CCCC's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
I respect the product at C4 Therapeutics Inc., but the stock at $3.37 is a different story. ROIC of -35%, FCF yield of -24.46%, and an Altman Z-Score of 0.2 place the company in the weakest fundamental and forensic zones of the RQD rating.. FCF yield is -24.46% and RQD sits at 29/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).